- PDS Biotechnology Corporation (NASDAQ:PDSB) announced updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial.
- The study is investigating PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) for the potential treatment of cervical cancer in patients with large tumors over 5 cm in size and/or cancer that has spread to the lymph nodes (lymph node metastasis).
- 100% (9/9) of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.
- Related: PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers.
- 89% (8/9) of patients treated with PDS0101 and CRT demonstrated a complete response (CR) on day 170. One patient who received 3 of the five scheduled doses of PDS0101 showed signs of residual disease.
- One patient with a CR died from an event unrelated to their underlying disease or treatment.
- 1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT.
- The toxicity of PDS0101 remains limited to low-grade local injection site reactions.
- PDS Biotech’s cash balance as of September 30, 2022, was approximately $71.6 million.
- Price Action: PDSB shares are up 27.40% at $7.13 on the last check Monday.
Investigating Amgen’s Standing In Biotechnology Industry Compared To Competitors
In today’s rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to…
